In Vitro Activities of β-Lactam-β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens

被引：29

作者：

Caverly, Lindsay J. ^{[1
]}

Spilker, Theodore ^{[1
]}

Kalikin, Linda M. ^{[1
]}

Stillwell, Terri ^{[1
]}

Young, Carol ^{[2
]}

Huang, David B. ^{[3
,4
]}

LiPuma, John J. ^{[1
]}

机构：

[1] Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA

[3] Motif BioSci, Princeton, NJ USA

[4] Rutgers New Jersey Med Sch, Trenton, NJ USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 01期

基金：

美国国家卫生研究院;

关键词：

cystic fibrosis; respiratory tract infection; ceftazidime-avibactam; ceftolozane-tazobactam; meropenem-vaborbactam; IDENTIFICATION; EPIDEMIOLOGY; GENE;

D O I：

10.1128/AAC.01595-19

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We tested the in vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, piperacillin-tazobactam, and 11 other antimicrobial agents against 420 Burkholderia, Achromobacter, Stenotrophomonas, and Pandoraea strains, 89% of which were cultured from respiratory specimens from persons with cystic fibrosis. Among the beta-lactam-beta-lactamase inhibitor agents, meropenem-vaborbactam had the greatest activity against Burkholderia and Achromobacter, including multidrug-resistant and extensively-drug-resistant strains. None of the newer beta-lactam-beta-lactamase combination drugs showed increased activity compared to that of the older agents against Stenotrophomonas maltophilia or Pandoraea spp.

引用

页数：4

共 14 条

[1]

[Anonymous], 2018, PERFORMANCE STANDARD

[2] Past and Present Perspectives on β-Lactamases [J].

Bush, Karen .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (10)

[3] Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice [J].

Caverly, Lindsay J. ;

LiPuma, John J. .

EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (10) :857-865

[4]

Coenye T, 2002, FEMS MICROBIOL LETT, V208, P15

[5] Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III [J].

Coenye, T ;

Spilker, T ;

Martin, A ;

LiPuma, JJ .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (09) :3300-3307

[6] Effect of β-Lactamase inhibitors on in vitro activity of β-Lactam antibiotics against Burkholderia cepacia complex species [J].

Everaert, Annelien ;

Coenye, Tom .

ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2016, 5

[7] The Changing Microbial Epidemiology in Cystic Fibrosis [J].

LiPuma, John J. .

CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (02) :299-+

[8] Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance [J].

Magiorakos, A. -P. ;

Srinivasan, A. ;

Carey, R. B. ;

Carmeli, Y. ;

Falagas, M. E. ;

Giske, C. G. ;

Harbarth, S. ;

Hindler, J. F. ;

Kahlmeter, G. ;

Olsson-Liljequist, B. ;

Paterson, D. L. ;

Rice, L. B. ;

Stelling, J. ;

Struelens, M. J. ;

Vatopoulos, A. ;

Weber, J. T. ;

Monnet, D. L. .

CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (03) :268-281

[9] Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients [J].

Papp-Wallace, Krisztina M. ;

Becka, Scott A. ;

Zeiser, Elise T. ;

Ohuchi, Nozomi ;

Mojica, Maria F. ;

Gatta, Julian A. ;

Falleni, Monica ;

Tosi, Delfina ;

Borghi, Elisa ;

Winkler, Marisa L. ;

Wilson, Brigid M. ;

LiPuma, John J. ;

Nukaga, Michiyoshi ;

Bonomo, Robert A. .

ACS INFECTIOUS DISEASES, 2017, 3 (07) :502-511

[10] Development of a recA gene-based identification approach for the the entire Burkholderia genus [J].

Payne, GW ;

Vandamme, P ;

Morgan, SH ;

LiPuma, JJ ;

Coenye, T ;

Weightman, AJ ;

Jones, TH ;

Mahenthiralingam, E .

APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2005, 71 (07) :3917-3927

← 1 2 →